本文關(guān)鍵詞： 貝前列素 纖溶酶 下肢動(dòng)脈硬化閉塞癥 氧化應(yīng)激 血液流變學(xué)　出處：《中國(guó)藥房》2017年29期 　論文類型：期刊論文

【摘要】：目的:觀察貝前列素聯(lián)合纖溶酶治療下肢動(dòng)脈硬化閉塞癥(LEAOD)的臨床療效及安全性。方法:選擇2015年1月-2016年1月于我院接受治療的82例LEAOD患者,采用隨機(jī)數(shù)字表法分為對(duì)照組和觀察組,各41例。所有患者在原發(fā)疾病的治療基礎(chǔ)上均給予低鹽、低脂飲食。對(duì)照組患者另給予纖溶酶注射液200單位,ivgtt,qd;觀察組患者在對(duì)照組基礎(chǔ)上加用貝前列素鈉片40μg,tid,飯后服用。兩組患者均治療15 d。比較兩組患者的臨床療效,治療前后的血液流變學(xué)指標(biāo)、踝肱指數(shù)、疼痛評(píng)分、冷感評(píng)分、間歇跛行評(píng)分和血清氧化應(yīng)激指標(biāo),記錄不良反應(yīng)發(fā)生情況。結(jié)果:觀察組患者的總有效率(90.24%)明顯高于對(duì)照組(78.05%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,兩組患者上述指標(biāo)比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患者的全血高切黏度、血漿黏度、血細(xì)胞比容、纖維蛋白原含量、血小板黏附率、疼痛評(píng)分、冷感評(píng)分、間歇跛行評(píng)分和血清丙二醛水平均較治療前明顯降低,踝肱指數(shù)、血清超氧化物歧化酶水平、總抗氧化能力和血清谷胱甘肽過氧化物酶水平均較治療前明顯升高,且觀察組各指標(biāo)均明顯優(yōu)于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:貝前列素聯(lián)合纖溶酶治療LEAOD的療效較好,能夠有效緩解患者臨床癥狀、促進(jìn)其局部血液循環(huán)、改善其氧化應(yīng)激水平,且安全性較高。
[Abstract]:Objective: to observe the clinical efficacy and safety of berprost combined with plasminase in the treatment of lower extremity arteriosclerosis obliterans (LEAODO). Methods: 82 patients with LEAOD received treatment from January 2015 to January 2016 in our hospital were selected. The patients were divided into control group (n = 41) and observation group (n = 41). All patients were treated with low salt on the basis of the treatment of primary diseases. Low fat diet. The patients in the control group were given another 200 units of plasminase injection iv GTT QD; the patients in the observation group were treated with 40 渭 g sodium berprost tablets after meals on the basis of the control group. The two groups were treated for 15 days. The clinical efficacy of the two groups was compared. Hemorheology index, ankle brachial index, pain score, cold feeling score, intermittent lameness score and serum oxidative stress index before and after treatment, Results: the total effective rate of patients in the observation group was significantly higher than that in the control group (P 0.05). The whole blood high shear viscosity, plasma viscosity, blood cell volume, fibrinogen content, platelet adhesion rate, pain score, cold feeling score, intermittent claudication score and serum malondialdehyde level were significantly lower than those before treatment, and ankle brachial index (malleolus index). The levels of serum superoxide dismutase (SOD), total antioxidant capacity and serum glutathione peroxidase (GSH) were significantly higher than those before treatment, and each index of the observation group was significantly better than that of the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: the efficacy of berprost combined with fibrinolytic enzyme in the treatment of LEAOD is better, which can effectively alleviate the clinical symptoms of patients and promote local blood circulation. The level of oxidative stress was improved and the safety was higher.
【作者單位】： 鄭州大學(xué)第五附屬醫(yī)院血管外科;
【基金】：河南省高等學(xué)校重點(diǎn)科研項(xiàng)目(No.16B320023)
【分類號(hào)】：R543.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張榮懷;王曉明;張丙芳;房海英;陳金鳳;王琳;;貝前列素鈉片治療老年下肢動(dòng)脈閉塞性疾病[J];中國(guó)藥物與臨床;2010年10期

2 王振峰;楊笑非;余宏;;貝前列素鈉片治療血栓閉塞性脈管炎的臨床觀察[J];中國(guó)藥物與臨床;2012年06期

3 周侖;王昭昭;黃葵;Q昧，

本文編號(hào)：1528376